Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – August 2010

Introduction

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – August 2010” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2010. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Highlights

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
[Fade out the market survey infos]

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Deal Summary 8
2.1 Pharmaceuticals & Healthcare, Global Deals Analysis, July 2010 8
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, July 2010 10
2.2.1 Gilead Sciences Completes Private Placement Of 1% Senior Notes For $1,100 Million 10
2.2.2 Infinity Pharmaceuticals Enters Into License Agreement With Intellikine 10
2.2.3 Eli Lilly Acquires Alnara Pharmaceuticals 10
2.2.4 Les Laboratoires Servier Enters Into Strategic Alliance With Galapagos 10
2.2.5 Mylan Announces Pricing Of Private Placement Of Senior Notes Due 2020 For $300 Million 11
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Value, July 2010 12
3 Pharmaceuticals & Healthcare, Deals Summary, by Type 13
3.1 Pharmaceuticals & Healthcare, Global, M&A, July 2010 13
3.1.1 M&A Deals in July 2010 14
3.1.2 Pharmaceuticals & Healthcare, Global M&A Deals, by Therapy Area, February 2010 – July 2010 15
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, July 2010 16
3.2.1 Equity Offering Deals in July 2010 17
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, February 2010 – July 2010 18
3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, July 2010 19
3.3.1 Debt Offering Deals in July 2010 20
3.3.2 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, February 2010 – July 2010 21
3.4 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, July 2010 22
3.4.1 PE/VC Deals in July 2010 23
3.4.2 Pharmaceuticals & Healthcare, Global, PE/VC, by Therapy Area, July 2010 24
3.4.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, July 2010 25
3.4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, February 2010 – July 2010 26
3.4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2010 – July 2010 27
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, July 2010 28
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, February 2010 – July 2010 29
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), July 2010 30
4.2.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Payment Mode, July 2010 31
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 32
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), February 2010 – July 2010 33
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 34
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2010 35
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2010 35
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payment and Deal Value (US$ m), July 2010 36
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, July 2010 37
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, July 2010 37
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, July 2010 37
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), February 2010 – July 2010 38
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payment Vs Milestone Payment (US$ m), February 2010 – July 2010 39
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Value (US$ m), February 2010 – July 2010 40
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payment Vs Milestone Payment (US$ m), February 2010 – July 2010 41
6 Deal Summary by Therapy Area 42
6.1 Pharmaceuticals & Healthcare, Oncology Deals, July 2010 42
6.1.1 Oncology – Deals of the Month 43
6.2 Pharmaceuticals & Healthcare, Central Nervous System Deals, July 2010 44
6.2.1 Central Nervous System – Deals of the Month 45
6.3 Pharmaceuticals & Healthcare, Infectious Disease Deals, July 2010 46
6.3.1 Infectious Disease – Deals of the Month 47
6.4 Pharmaceuticals & Healthcare, Immunology Deals, July 2010 48
6.4.1 Immunology – Deals of the Month 49
6.5 Pharmaceuticals & Healthcare, Cardiovascular Deals, July 2010 50
6.5.1 Cardiovascular – Deals of the Month 51
6.6 Pharmaceuticals & Healthcare, Gastrointestinal Deals, July 2010 52
6.6.1 Gastrointestinal – Deals of the Month 53
6.7 Pharmaceuticals & Healthcare, Metabolic Disorders Deals, July 2010 54
6.7.1 Metabolic Disorders – Deals of the Month 55
7 Deal Summary by Geography 56
7.1 Pharmaceuticals & Healthcare, North America Region Deals, July 2010 56
7.1.1 North America – Deals of the Month 57
7.2 Pharmaceuticals & Healthcare, Europe Region Deals, July 2010 58
7.2.1 Europe – Deals of the Month 59
7.3 Pharmaceuticals & Healthcare, Asia-Pacific Deals, July 2010 60
7.3.1 Asia-Pacific – Deals of the Month 61
7.4 Pharmaceuticals & Healthcare, Rest of the World Deals, July 2010 62
7.4.1 Rest of the World – Deals of the Month 63
8 Pharmaceuticals & Healthcare, Top Advisors 64
8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, February 2010 – July 2010 64
8.2 Pharmaceuticals & Healthcare, Top Financial Advisors, Equity Offerings, February 2010 – July 2010 65
8.3 Pharmaceuticals & Healthcare, Top Financial Advisors, Debt Offerings, February 2010 – July 2010 66
9 Further Information 67
9.1 Methodology 67
9.2 About GlobalData 67
9.3 Contact Us 68
9.4 Disclosure information 68
9.5 Disclaimer 68
[Fade out table of contents]

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 9
Table 2: Pharmaceuticals & Healthcare, Global, Top Deals, July 2010 10
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Value (%), July 2010 12
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 13
Table 5: Pharmaceuticals & Healthcare, Global, M&A Deals, July 2010 14
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Value (US$ m), by Therapy Area, February 2010 – July 2010 15
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 16
Table 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, July 2010 17
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 18
Table 10: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 19
Table 11: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, July 2010 20
Table 12: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 21
Table 13: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 22
Table 14: Pharmaceuticals & Healthcare, Global, PE/VC Deals, July 2010 23
Table 15: Pharmaceuticals & Healthcare, Global, PE/VC Deals, by Therapy Area, Deals Summary, February 2010 – July 2010 24
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Value (%), July 2010 25
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 26
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2010 – July 2010 27
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 28
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 29
Table 21: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 30
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Value (US$ m), July 2010 31
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 32
Table 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, February 2010 – July 2010 33
Table 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 34
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 35
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 36
Table 28: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Value, July 2010 37
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, July 2010 37
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, July 2010 37
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 38
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), July 2010 39
Table 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, February 2010 – July 2010 40
Table 34: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), July 2010 41
Table 35: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 43
Table 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 45
Table 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 47
Table 38: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 49
Table 39: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 51
Table 40: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 52
Table 41: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 54
Table 42: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 57
Table 43: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 59
Table 44: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 61
Table 45: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 62
Table 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 64
Table 47: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 65
Table 48: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Debt Offerings, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 66
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 8
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Value (%), July 2010 12
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, February 2010 – July 2010 15
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 18
Figure 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 19
Figure 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 21
Figure 9: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 22
Figure 10: Pharmaceuticals & Healthcare, Global, PE/VC Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, February 2010 – July 2010 24
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Value (%), July 2010 25
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 26
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 28
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 29
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 30
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 32
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, February 2010 – July 2010 33
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 34
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 35
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 38
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), February 2010 – July 2010 39
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Value (US$ m), February 2010 – July 2010 40
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), July 2010 41
Figure 25: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 42
Figure 26: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 44
Figure 27: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 46
Figure 28: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 48
Figure 29: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 50
Figure 30: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 52
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 54
Figure 32: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 56
Figure 33: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 58
Figure 34: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 60
Figure 35: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 62
Figure 36: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 64
Figure 37: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 65
Figure 38: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Debt Offerings, Number of Deals and Deal Value (US$ m), February 2010 – July 2010 66
[Fade out list of tables / figures]